Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LDLR | P01130 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17064457 | 1.00 | ACHE (0.37) | ACHEBCHEHDAC3HDAC4HDAC1 | |
| SCHEMBL18623191 | 1.00 | ACHE (0.37) | ACHEBCHEHDAC3HDAC4HDAC1 | |
| SCHEMBL29245887 | 0.89 | BCHE (0.36) | ACHEBCHEHDAC3HDAC4HDAC1 | |
| SCHEMBL18623202 | 0.86 | MAPT (0.39) | ALDH1A1KMT2A | |
| SCHEMBL17064520 | 0.86 | MAPT (0.39) | ALDH1A1KMT2A | |
| SCHEMBL18604794 | 0.86 | MAPT (0.39) | ALDH1A1KMT2A | |
| SCHEMBL18604872 | 0.84 | ALDH1A1 (0.46) | KDM4ELDLRALDH1A1LMNA | |
| SCHEMBL18623188 | 0.84 | ALDH1A1 (0.46) | KDM4ELDLRALDH1A1LMNA | |
| SCHEMBL23119549 | 0.84 | CYP2C9 (0.45) | ATMALDH1A1LMNAKMT2A | |
| SCHEMBL17064314 | 0.83 | SIGMAR1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-10689346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633345-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-10-24 | — | — | US | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-13 | — | — | US | disclosed |
| US-10125102-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-13 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| EP-3113772-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134998-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ACHE 812/4885BCHE 589/4885HDAC3 2319/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ACHE 812/4885BCHE 589/4885HDAC3 2319/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ACHE 812/4885BCHE 589/4885HDAC3 2319/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ACHE 617/4885BCHE 482/4885HDAC3 2570/4885 |
| US-10329260-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
| US-10125102-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
| US-10633345-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ACHE 812/4885BCHE 589/4885HDAC3 2319/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ACHE 812/4885BCHE 589/4885HDAC3 2319/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ACHE 991/4885BCHE 541/4885HDAC3 2370/4885 |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ACHE 812/4885BCHE 589/4885HDAC3 2319/4885 |
| US-10689346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ACHE 535/4885BCHE 435/4885HDAC3 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.